Simulations Plus (NASDAQ:SLP) Posts Earnings Results, Beats Estimates By $0.06 EPS

Simulations Plus (NASDAQ:SLP - Get Free Report) posted its quarterly earnings data on Thursday. The technology company reported $0.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.25 by $0.06, Zacks reports. Simulations Plus had a net margin of 10.97% and a return on equity of 6.84%. The firm had revenue of $22.43 million during the quarter, compared to the consensus estimate of $21.93 million. During the same quarter in the previous year, the firm posted $0.20 EPS. The business's revenue for the quarter was up 22.5% compared to the same quarter last year. Simulations Plus updated its FY25 guidance to $1.07-1.20 EPS and its FY 2025 guidance to 1.070-1.200 EPS.

Simulations Plus Trading Down 2.3 %

SLP stock traded down $0.58 during trading on Tuesday, hitting $24.25. 275,469 shares of the company's stock were exchanged, compared to its average volume of 175,875. The stock has a market capitalization of $487.23 million, a price-to-earnings ratio of 60.63 and a beta of 1.13. The business has a 50-day moving average price of $29.84 and a two-hundred day moving average price of $30.22. Simulations Plus has a 52-week low of $23.01 and a 52-week high of $51.22.

Analyst Ratings Changes

Several research firms have recently weighed in on SLP. William Blair reissued an "outperform" rating on shares of Simulations Plus in a research report on Wednesday, January 8th. StockNews.com raised Simulations Plus from a "sell" rating to a "hold" rating in a report on Friday. Finally, KeyCorp lifted their price target on Simulations Plus from $35.00 to $37.00 and gave the company an "overweight" rating in a research report on Friday, January 24th. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Simulations Plus presently has a consensus rating of "Moderate Buy" and an average price target of $49.40.

Insider Buying and Selling

In related news, Director Walter S. Woltosz sold 20,000 shares of the firm's stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $33.91, for a total transaction of $678,200.00. Following the sale, the director now directly owns 3,402,584 shares in the company, valued at approximately $115,381,623.44. This trade represents a 0.58 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 19.40% of the company's stock.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.